Hereditary Angioedema Clinical Trial
— RAPIDe-1Official title:
A Phase II, Double-blind, Placebo-controlled, Randomized, Cross-over, Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema Due to C1-inhibitor Deficiency Type I and II
Verified date | June 2023 |
Source | Pharvaris Netherlands B.V. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy of orally administered deucrictibant for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of deucrictibant and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks and safety of each dose of deucrictibant with placebo.
Status | Completed |
Enrollment | 74 |
Est. completion date | March 1, 2023 |
Est. primary completion date | September 23, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Key Inclusion Criteria: 1. Signed and dated informed consent form 2. Diagnosis of HAE type I or II 3. Documented history of HAE attacks: at least three in the last 4 months, or at least two in the last 2 months prior to screening 4. Reliable access and experience to use standard of care acute attack medications Key Exclusion Criteria: 1. Pregnancy or breast-feeding 2. Clinically significant abnormal electrocardiogram 3. Any other systemic disease or significant disease or disorder that would interfere with the patient's safety or ability to participate in the study 4. Use of C1-esterase inhibitor, oral kallikrein inhibitors, attenuated androgens, anti-fibrinolytics, or monoclonal HAE therapy within a defined period prior to enrollment 5. Positive serology for HIV or active infection with hepatitis B virus or hepatitis C virus 6. Abnormal hepatic function 7. Abnormal renal function 8. History of alcohol or drug abuse within defined period, or current evidence of substance dependence or abuse 9. History of documented severe hypersensitivity to any medicinal product 10. Participation in any other investigational drug study within defined period |
Country | Name | City | State |
---|---|---|---|
Bulgaria | Study site | Sofia | |
Canada | Study site | Edmonton | Alberta |
Canada | Study site | Montréal | Quebec |
Canada | Study site | Ottawa | Ontario |
Canada | Study site | Québec City | Quebec |
Canada | Study site | Toronto | Ontario |
Czechia | Study site | Brno | |
Czechia | Study site | Hradec Králové | |
France | Study site | Grenoble | |
France | Study site | Montpellier | |
France | Study site | Paris | |
Germany | Study site | Berlin | |
Germany | Study site | Dresden | |
Germany | Study site | Frankfurt | |
Germany | Study site | Mainz | |
Germany | Study site | Ulm | |
Hungary | Study site | Budapest | |
Israel | Study site | Ashkelon | |
Israel | Study site | Haifa | |
Israel | Study site | Tel Aviv | |
Italy | Study site | Monserrato | |
Italy | Study site | Naples | |
Netherlands | Study site | Amsterdam | |
Poland | Study site | Kraków | |
Spain | Study site | Barcelona | |
Spain | Study site | Madrid | |
United Kingdom | Study site | Brighton | |
United Kingdom | Study site | London | |
United States | Study site | Birmingham | Alabama |
United States | Study site | Chevy Chase | Maryland |
United States | Study site | Hershey | Pennsylvania |
United States | Study site | Paradise Valley | Arizona |
United States | Study site | Saint Louis | Missouri |
United States | Study site | San Diego | California |
United States | Study site | Santa Monica | California |
United States | Study site | Walnut Creek | California |
Lead Sponsor | Collaborator |
---|---|
Pharvaris Netherlands B.V. |
United States, Bulgaria, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of the 3-symptom composite visual analogue scale (VAS-3) score from pre-treatment to 4 hours post-treatment | VAS-3 scores range between 0 and 100. A larger reduction means a better outcome. | Pre-treatment and 4 hours post-treatment | |
Secondary | Time to onset of symptom relief by visual analogue scale (VAS-3) score | VAS-3 scores range between 0 and 100. Symptom relief is defined as a 50% or higher reduction of the VAS-3 score from the pre-treatment value. | Assessed from pre-treatment to 48 hours post-treatment | |
Secondary | Proportion of study drug treated attacks requiring HAE rescue medication | Qualifying attacks treated with study drug may use approved rescue medication if no symptom relief within 4 h has been experienced. | Assessed at 4 hours post-study drug treatment | |
Secondary | Time to onset of almost complete and complete symptom relief by visual analogue scale (VAS-3) | VAS scores range between 0 and 100. Almost complete symptom relief is defined as all 3 individual VAS scores of the VAS-3 having a value < 10. Complete symptom relief is defined as all 3 individual VAS scores are of the VAS-3 having a value of 0. | Assessed from pre-treatment to 48 hours post-treatment | |
Secondary | Mean symptom complex severity (MSCS) score | MSCS scores range between 0 and 3. A higher score means a worse outcome. | 4 hours post-treatment | |
Secondary | Treatment outcome score (TOS) | TOS scores range between -100 and 100. A positive score indicates improvement, a score of 0 indicates no change, and a negative score indicates worsening compared to pre-treatment. | Pre-treatment and 4 hours post-treatment | |
Secondary | Treatment satisfaction questionnaire for medication (TSQM) scores | TSQM scores range from 0 to 100. A higher score means a better outcome. | 48 hours post-treatment | |
Secondary | Treatment-emergent adverse events (TEAEs) | From post-dose non-attack visit through study completion, approximately 26 weeks | ||
Secondary | Treatment-related adverse events (AEs) | From post-dose non-attack visit through study completion, approximately 26 weeks | ||
Secondary | Treatment-emergent serious adverse events (TESAEs) | From post-dose non-attack visit through study completion, approximately 26 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06007677 -
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
|
Phase 2 | |
Completed |
NCT00997204 -
EASSI - Evaluation of the Safety of Self-Administration With Icatibant
|
Phase 3 | |
Completed |
NCT00438815 -
Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks
|
Phase 3 | |
Completed |
NCT00748202 -
Berinert P Study of Subcutaneous Versus Intravenous Administration
|
Phase 3 | |
Completed |
NCT01426763 -
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase
|
Phase 2 | |
Terminated |
NCT04091113 -
Hereditary Angioedema Kininogen Assay
|
||
Completed |
NCT00432510 -
Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects
|
Phase 1 | |
Completed |
NCT03712228 -
A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
|
Phase 2 | |
Active, not recruiting |
NCT05453968 -
Berotralstat Treatment in Children With Hereditary Angioedema
|
Phase 3 | |
Recruiting |
NCT05511922 -
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
|
Phase 3 | |
Recruiting |
NCT05505916 -
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
|
Phase 3 | |
Completed |
NCT02303626 -
12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02159430 -
Hereditary AngioEdema, Neurobiology and Psychopathology
|
N/A | |
Completed |
NCT01984788 -
Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE
|
Phase 2 | |
Completed |
NCT04888650 -
Assessment of the State of Health, Quality of Life and Expectations of Patients With Hereditary Angioedema
|
||
Completed |
NCT02448264 -
First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers
|
Phase 1 | |
Completed |
NCT05118958 -
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
|
Phase 1 | |
Completed |
NCT06414252 -
Social Evaluated Cold Pressor Test in Hereditary Angioedema Patients
|
||
Active, not recruiting |
NCT04739059 -
Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks
|
Phase 3 | |
Completed |
NCT02819102 -
An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates
|
Phase 1 |